This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Bpc-157 as an active pharmaceutical ingredient (API)
Exercise caution or avoid with: Ready to put this into practice
[1] [2] Routine consultation with a healthcare provider is appropriate when: Bloating persists beyond 2-3 weeks despite dietary modifications and dose stabilization Symptoms significantly impair quality of life or daily functioning Bloating is accompanied by persistent nausea, early satiety, or regurgitation, which may suggest severe gastroparesis New or worsening heartburn or reflux symptoms develop There is concern about medication interactions or the need for dose adjustment Healthcare providers should evaluate for potential complications of tirzepatide therapy, including acute pancreatitis (characterized by severe epigastric pain radiating to the back, nausea, and elevated lipase levels) and severe gastroparesis
While semaglutide activates only the GLP-1 receptor and tirzepatide targets both GLP-1 and GIP receptors, retatrutide activates all three metabolic hormone receptors: GLP-1, GIP, and glucagon
